Illumina (ILMN) Will Require 'Significant Investment' to Compete with Sequenom (SQNM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Sequenom (SQNM) Prelim FY12 Revs Come in Ahead of Views
January 7, 2013 6:26 AM ESTSequenom, Inc. (NASDAQ: SQNM) announced preliminary highlights of the Company's 2012 performance and accomplishments.
Initial 2012 Performance Results (unaudited)
* Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012. The Street was looking for revs of $85.3 million.
* Diagnostic services revenues of approximately $46 million,... More
Illumina (ILMN) to Acquire Verinata Health in $450M Deal
January 7, 2013 5:58 AM ESTIllumina, Inc. (Nasdaq: ILMN) has signed a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities, for consideration of $350 million plus up to $100 million in milestone payments through 2015. Upon completion of the acquisition, Illumina will have access to Verinatas verifi® prenatal test, the broadest non-invasive prenatal test (NIPT) available today for high-risk pregnancies, and to the most comprehensive intellectual property portfolio in the non-invasive prenatal test industry. As non-invasive prenatal testing is one of the most rapidly growing areas utilizing next-generation sequencing,... More
